<DOC>
	<DOCNO>NCT01435759</DOCNO>
	<brief_summary>This study examine SPD489 subject age 18-65 major depressive disorder ( MDD ) take certain type antidepressant continue residual depression symptom . The purpose study help answer following question : - How safe SPD489 supplemental treatment depression side effect might relate ? - Can SPD489 help patient depression also take antidepressant ? - How much SPD489 give patient depression also take antidepressant ? - How SPD489 compare placebo depressed patient also take antidepressant ?</brief_summary>
	<brief_title>SPD489 Combination With Antidepressant Treatment Adults With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Inclusion Criteria 1 . Subject able provide write , personally sign date informed consent participate study complete studyrelated procedure . 2 . Subject 1865 year age . 3 . Subject primary diagnosis nonpsychotic MDD . 4 . Subject MADRS total score 24 5 . Subject willing understanding ability fully comply study procedure restriction define protocol . 6 . Subject , female , must negative serum beta human chorionic gonadotropin ( HCG ) pregnancy test negative urine pregnancy test agree comply applicable contraceptive requirement . 7 . Subject able swallow capsule . Exclusion Criteria 1 . Subject whose current episode MDD respond adequate treatment regimen . 2 . Subject lifetime history treatment resistant depression , define responded adequate treatment 2 treatment regimen . 3 . Subject current comorbid psychiatric disorder either control medication prohibit study uncontrolled associate significant symptom . 4 . Subject hospitalize ( within last 12 month ) current MDD episode . 5 . Subject current lifetime history attentiondeficit/hyperactivity disorder ( ADHD ) . 6 . Subject first degree relative diagnose bipolar I disorder . 7 . Subject recent history ( within last 6 month ) suspect substance abuse dependence disorder . 8 . Subject consider suicide risk , previously make suicide attempt within past 3 year , currently demonstrate active suicidal ideation . 9 . Subject concurrent chronic acute illness unstable medical condition . 10 . Subject history seizure ( infantile febrile seizure ) , tic disorder , current diagnosis and/or know family history Tourette 's Disorder , serious neurological disease , history significant head trauma , dementia , cerebrovascular disease , Parkinson 's disease , intracranial lesion . 11 . Subject known history symptomatic cardiovascular disease , advanced arteriosclerosis , structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , coronary artery disease , serious cardiac problem may place increased vulnerability sympathomimetic effect stimulant medication . 12 . Subject history thyroid disorder stabilize thyroid medication treatment within 3 month prior Screening Visit . 13 . Subject know family history sudden cardiac death ventricular arrhythmia . 14 . Subject glaucoma . 15 . Subject clinically significant ECG clinical laboratory abnormality Screening Visit . 16 . Subject history moderate severe hypertension . 17 . Current use medication ( include overthecounter [ OTC ] , herbal homeopathic preparation ) central nervous system effect . 18 . Subject potential need initiate modify frequency psychotherapy continue initiate treatment depression , outside allow protocol . 19 . Subject electroconvulsive therapy current depressive episode 3 month prior Leadin Baseline Visit . 20 . The subject know suspected intolerance hypersensitivity investigational product . 21 . The subject know suspected intolerance hypersensitivity possible antidepressant treatment ( escitalopram oxalate venlafaxine HCL extend release . 22 . Subject positive urine drug result . 23 . Subject body mass index &lt; 18.5 &gt; 40 . 24 . Subject female pregnant nursing . 25 . Subject participate another clinical study involve SPD489/NRP104 previously use commercial lisdexamfetamine dimesylate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>